Patents Assigned to Silence Therapeutics GmbH
-
Publication number: 20200095580Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.Type: ApplicationFiled: April 5, 2018Publication date: March 26, 2020Applicant: SILENCE THERAPEUTICS GMBHInventors: Judith HAUPTMANN, Dmitry SAMARSKY, Christian FRAUENDORF
-
Publication number: 20190390201Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 3, 2019Publication date: December 26, 2019Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 10329568Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: September 5, 2018Date of Patent: June 25, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 10323246Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 15, 2017Date of Patent: June 18, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20190119676Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.Type: ApplicationFiled: April 5, 2017Publication date: April 25, 2019Applicant: Silence Therapeutics GmbHInventors: Christian FRAUENDORF, Mak CAMERON
-
Patent number: 10266829Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: June 20, 2018Date of Patent: April 23, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20190024089Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: September 5, 2018Publication date: January 24, 2019Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20180291381Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: June 20, 2018Publication date: October 11, 2018Applicant: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20180223286Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 15, 2017Publication date: August 9, 2018Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 9790501Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 8, 2017Date of Patent: October 17, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9790505Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 12, 2017Date of Patent: October 17, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9783802Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 12, 2017Date of Patent: October 10, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9758784Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 8, 2017Date of Patent: September 12, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20170247698Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 8, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247697Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 8, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247691Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247707Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 9695423Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: December 22, 2015Date of Patent: July 4, 2017Assignee: SILENCE THERAPEUTICS GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9486538Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: GrantFiled: August 28, 2015Date of Patent: November 8, 2016Assignee: SILENCE THERAPEUTICS GMBHInventors: Oliver Keil, Jörg Kaufmann, Ansgar Santel
-
Patent number: 9458461Abstract: The present invention is related to an siRNA comprising an antisense strand and a sense strand, wherein all or a portion of said antisense strand comprises an antisense duplex region, wherein all or a portion of said sense strand comprises a sense duplex region, wherein said antisense duplex region is at least partially complementary to said sense duplex region, wherein said siRNA comprises a duplex region consisting of said antisense duplex region and said sense duplex region, and wherein: a) said antisense strand comprises a nucleotide sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 68, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102 or 104; or b) said antisense strand comprises an antisense duplex region, all or a portion of which, is complementary to a portion of SEQ ID NO: 1 or 70.Type: GrantFiled: May 29, 2014Date of Patent: October 4, 2016Assignee: SILENCE THERAPEUTICS GMBHInventors: Ansgar Santel, Jörg Kaufmann, Martin Witzenrath